Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis
Igne Sinkeviciute, Marieke J.H. Begemann, Merel Prikken, et al.
Schizophrenia (2018) Vol. 4, Iss. 1
Open Access | Times Cited: 79

Showing 1-25 of 79 citing articles:

Nonsocial and social cognition in schizophrenia: current evidence and future directions
Michael F. Green, William P. Horan, Junghee Lee
World Psychiatry (2019) Vol. 18, Iss. 2, pp. 146-161
Open Access | Times Cited: 499
Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment
Robert A. McCutcheon, Richard S.E. Keefe, Philip McGuire
Molecular Psychiatry (2023) Vol. 28, Iss. 5, pp. 1902-1918
Open Access | Times Cited: 320
Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations
Amanda McCleery, Keith H. Nuechterlein
Dialogues in Clinical Neuroscience (2019) Vol. 21, Iss. 3, pp. 239-248
Open Access | Times Cited: 179
Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art
Philip D. Harvey, Marta Bosia, Roberto Cavallaro, et al.
Schizophrenia Research Cognition (2022) Vol. 29, pp. 100249-100249
Open Access | Times Cited: 95
European Psychiatric Association guidance on treatment of cognitive impairment in schizophrenia
Antonio Vita, Wolfgang Gäebel, Armida Mucci, et al.
European Psychiatry (2022) Vol. 65, Iss. 1
Open Access | Times Cited: 86
The schizophrenia syndrome, circa 2024: What we know and how that informs its nature
Rajiv Tandon, Henry A. Nasrallah, Schahram Akbarian, et al.
Schizophrenia Research (2023) Vol. 264, pp. 1-28
Open Access | Times Cited: 60
The Role of Estrogen Receptors and Their Signaling across Psychiatric Disorders
Wu Jeong Hwang, Tae Young Lee, Nahrie Suk Kim, et al.
International Journal of Molecular Sciences (2020) Vol. 22, Iss. 1, pp. 373-373
Open Access | Times Cited: 127
Multi-outcome meta-analysis (MOMA) of cognitive remediation in schizophrenia: Revisiting the relevance of human coaching and elucidating interplay between multiple outcomes
Lana Kambeitz‐Ilankovic, Linda T. Betz, Clara Dominke, et al.
Neuroscience & Biobehavioral Reviews (2019) Vol. 107, pp. 828-845
Open Access | Times Cited: 80
Abnormal synaptic pruning during adolescence underlying the development of psychotic disorders
M. Germann, Sanne Brederoo, Iris E. Sommer
Current Opinion in Psychiatry (2021) Vol. 34, Iss. 3, pp. 222-227
Open Access | Times Cited: 67
Towards Enhancing Drug Development Methodology to Treat Cognitive Impairment Associated With Schizophrenia and Other Neuropsychiatric Conditions: Insights From 2 Decades of Clinical Trials
W. P. Horan, Amir H Kalali, Stephen K. Brannan, et al.
Schizophrenia Bulletin (2025)
Open Access | Times Cited: 1
The effects of eszopiclone on sleep spindles and memory consolidation in schizophrenia: a randomized clinical trial
Dimitrios Mylonas, Bengi Baran, Charmaine Demanuele, et al.
Neuropsychopharmacology (2020) Vol. 45, Iss. 13, pp. 2189-2197
Open Access | Times Cited: 58
Intrinsic Connectivity Patterns of Task-Defined Brain Networks Allow Individual Prediction of Cognitive Symptom Dimension of Schizophrenia and Are Linked to Molecular Architecture
Chen Ji, Veronika I. Müller, Juergen Dukart, et al.
Biological Psychiatry (2020) Vol. 89, Iss. 3, pp. 308-319
Open Access | Times Cited: 58
The Direct and Long-Term Effects of Raloxifene as Adjunctive Treatment for Schizophrenia-Spectrum Disorders: A Double-Blind, Randomized Clinical Trial
Bodyl A. Brand, Janna N. de Boer, Machteld Marcelis, et al.
Schizophrenia Bulletin (2023) Vol. 49, Iss. 6, pp. 1579-1590
Open Access | Times Cited: 19
Effect of transcranial direct current stimulation with concurrent cognitive performance targeting posterior parietal cortex vs prefrontal cortex on working memory in schizophrenia: a randomized clinical trial
Wenpeng Hou, Fuchun Zhou, Qi Wang, et al.
Translational Psychiatry (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 7
The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia
Samantha E. Yohn, P.D. Harvey, Stephen K. Brannan, et al.
Frontiers in Psychiatry (2024) Vol. 15
Open Access | Times Cited: 7
Effects of chronic stress on cognitive function – From neurobiology to intervention
Milena Girotti, Sarah E. Bulin, Flavia Carreño
Neurobiology of Stress (2024) Vol. 33, pp. 100670-100670
Open Access | Times Cited: 6
Effects of bilateral, bipolar-nonbalanced, frontal transcranial Direct Current Stimulation (tDCS) on negative symptoms and neurocognition in a sample of patients living with schizophrenia: Results of a randomized double-blind sham-controlled trial
Jacopo Lisoni, Giulia Baldacci, Gabriele Nibbio, et al.
Journal of Psychiatric Research (2022) Vol. 155, pp. 430-442
Closed Access | Times Cited: 26
Effect of Vagus Nerve Stimulation on Attention and Working Memory in Neuropsychiatric Disorders: A Systematic Review
Daruj Aniwattanapong, Justine List, Nithya Ramakrishnan, et al.
Neuromodulation Technology at the Neural Interface (2022) Vol. 25, Iss. 3, pp. 343-355
Closed Access | Times Cited: 23
The potential effect of metformin on cognitive and other symptom dimensions in patients with schizophrenia and antipsychotic-induced weight gain: a systematic review, meta-analysis, and meta-regression
Vera Battini, Giovanna Cirnigliaro, Rodolfo Leuzzi, et al.
Frontiers in Psychiatry (2023) Vol. 14
Open Access | Times Cited: 15
Neurocognitive Deficits in First-Episode and Chronic Psychotic Disorders: A Systematic Review from 2009 to 2022
Nadja Tschentscher, Christian Franz Josef Woll, Julia C. Tafelmaier, et al.
Brain Sciences (2023) Vol. 13, Iss. 2, pp. 299-299
Open Access | Times Cited: 14
Neural changes following cognitive remediation therapy for schizophrenia
Yasuhiro Matsuda, Manabu Makinodan, Tsubasa Morimoto, et al.
Psychiatry and Clinical Neurosciences (2019) Vol. 73, Iss. 11, pp. 676-684
Open Access | Times Cited: 38
N-Acetylcysteine (NAC) in Schizophrenia Resistant to Clozapine: A Double-Blind, Randomized, Placebo-Controlled Trial Targeting Negative Symptoms
Erica Neill, Susan L. Rossell, Caitlin Yolland, et al.
Schizophrenia Bulletin (2022) Vol. 48, Iss. 6, pp. 1263-1272
Open Access | Times Cited: 22
Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs
Guillaume Fond, Jasmina Mallet, Mathieu Urbach, et al.
BMJ Mental Health (2023) Vol. 26, Iss. 1, pp. e300771-e300771
Open Access | Times Cited: 12
Cognitive impairment in schizophrenia is associated with prefrontal–striatal functional hypoconnectivity and striatal dopaminergic abnormalities
Kai‐Chun Yang, Bang‐Hung Yang, Mu‐N Liu, et al.
Journal of Psychopharmacology (2024) Vol. 38, Iss. 6, pp. 515-525
Closed Access | Times Cited: 4
Effects of tDCS with concurrent cognitive performance targeting the dorsolateral prefrontal cortex and the posterior parietal cortex on EEG microstates in schizophrenia
Xiangqin Qin, Qi Wang, Hang Li, et al.
Schizophrenia Research (2025) Vol. 277, pp. 117-123
Closed Access
Page 1 - Next Page

Scroll to top